Trevi Therapeutics presents single-asset pipeline focused on chronic cough. The biotech company is advancing nalbuphine ER, an investigational therapy with a differentiated dual mechanism targeting both peripheral lung and central brain pathways involved in the cough reflex. Trevi has demonstrated positive clinical data in two major indications: idiopathic pulmonary fibrosis related cough and refractory chronic cough, positioning itself as the only therapy with efficacy data in both conditions. The company projects peak sales exceeding six billion dollars and plans a specialty sales model for market launch. With a significant unmet need in difficult-to-treat chronic cough conditions, Trevi aims to address a major gap in available treatment options for patients with these debilitating conditions.
Post from MarketNews_en
Log in to interact with content.